FILTER

Refine your search with the following facets to narrow down your results.

2,770 Current news about the topic medicine

GlaxoSmithKline and Roche announce co-development and co-promotion agreement

10-Dec-2001 - Basel and London, December 7, 2001 -- GlaxoSmithKline plc and Roche announced that they have signed an agreement to co-develop and co-promote ibandronate, currently in Phase III clinical development, for the treatment and prevention of postmenopausal osteoporosis. Given the promising clinical ...

clinical trials food medicine +2

Millennium and COR Therapeutics Agree to Merge, Creating Integrated Biopharmaceutical Company

07-Dec-2001 - Millennium Pharmaceuticals, Inc. and COR Therapeutics, Inc. today announced that they have signed a definitive agreement for Millennium to acquire COR in a stock-for-stock exchange valued at $2.0 billion. The combined company will be named Millennium Pharmaceuticals, Inc., with worldwide ...

clinical trials inflammation metabolic diseases +1

Aventis and the Nobel Foundation Launch New Section of Nobel E-museum

05-Dec-2001 - Frankfurt, Germany and Stockholm, Sweden - Aventis and the Nobel Foundation today announced the completion of the first release of the Aventis-sponsored medical section of "Science and Technology", the Web-based expansion of the Nobel e-museum (NeM). The section will be accessible online as of ...

Germany medicine plasma +1

Boehringer Ingelheim and ImmunoGen Sign Exclusive License Agreement

29-Nov-2001 - Ingelheim, Germany and Cambridge, Massachusetts, November 28, 2001 – Boehringer Ingelheim International GmbH and ImmunoGen, Inc. (Nasdaq: IMGN) today announced a collaboration to develop a new product combining ImmunoGen’s maytansinoid Tumor-Activated Prodrug (TAP) technology with a Boehringer ...

antibodies biopharmaceuticals clinical trials +5

Abgenix Acquires Catalytic Antibody Technology

14-Nov-2001 - FREMONT, Calif., November 13, 2001 - Abgenix, Inc. announced today that it acquired Hesed Biomed, Inc., a privately-held biotechnology company with significant intellectual property and technology in the field of catalytic antibodies. A catalytic antibody (CAb) is a type of monoclonal antibody ...

antibodies biotechnology diseases +5

Ilex and Millennium Agree to Restructure Ownership in Campath®

30-Oct-2001 - CAMBRIDGE, Mass. and SAN ANTONIO, Texas (October 29, 2001) - Millennium Pharmaceuticals, Inc. and ILEX™ Oncology, Inc. today announced that they have signed a definitive agreement to restructure their 50-50 joint venture, Millennium & ILEX Partners, L.P. (M&I Partners). As a result of this ...

Japan joint ventures oncology +1

Amgen Submits Aranesp™ License Supplement To European Agency For The Treatment Of Anemia Associated With Chemotherapy

24-Oct-2001 - THOUSAND OAKS, Calif., October 23, 2001 -- Amgen announced it had submitted a variation application to the European Agency for the Evaluation of Medicinal Products (EMEA) to expand the clinical indication for Aranesp™ (darbepoetin alfa), its new anemia therapy. The new indication sought is for ...

anemia chemotherapy chronic renal failure +5

New data on Novartis drug Zometa for treatment of breast cancer and multiple myeloma-related bone complications published

23-Oct-2001 - Basel, 22 October 2001 – Clinical data published in the September 2001 issue of The Cancer Journal demonstrate that the Novartis drug Zometa (zoledronic acid) reduces the incidence of cancer-related bone complications called skeletal related events (SREs) in patients with multiple myeloma or ...

acids bone metastases breast cancer +11

Novartis submits supplemental NDA with US FDA for Glivec® for treatment of certain GI tumors

22-Oct-2001 - Novartis announced today that it has submitted a supplementary New Drug Application (sNDA) to the US Food and Drug Administration (FDA), seeking marketing authorisation for its novel drug Glivec® (imatinib)* for the treatment of patients with unresectable (inoperable) and/or metastatic malignant ...

chemotherapy chronic myeloid leukemia food +6

Alfred Sommer Receives The Bristol-Myers Squibb/Mead Johnson Award For Distinguished Achievement In Nutrition Research

15-Oct-2001 - EVANSVILLE, INDIANA (October 12, 2001) -- Alfred Sommer, M.D., M.H.S., is the recipient of the 21st Annual Bristol-Myers Squibb/Mead Johnson Award for Distinguished Achievement in Nutrition Research for his contributions to our understanding of the origin, magnitude and control of nutritional ...

blindness diarrhea infectious diseases +5